fludarabine


Also found in: Wikipedia.

fludarabine

 [floo-dar´ah-bēn]
an adenine analogue and purineantimetabolite that inhibits DNA synthesis; administered intravenously as the phosphate salt as an antineoplastic agent in the treatment of chronic lymphocytic leukemia.

fludarabine

/flu·dar·a·bine/ (floo-dar´ah-bēn) an adenine analogue and purine antimetabolite used as the phosphate salt as an antineoplastic in the treatment of chronic lymphocytic leukemia.

fludarabine

an antimetabolite used to treat neoplasia.
indications It is prescribed in the treatment of patients with B cell chronic lymphocytic leukemia and as salvage therapy for non-Hodgkin's lymphoma and acute leukemias.
contraindications It should not be given to patients who are pregnant or hypersensitive to this drug or its components. Patients should be closely observed for signs of hematologic and nonhematologic toxicity (e.g., edema, fatigue, myalgias).
adverse effects It is a potent antineoplastic agent with potentially significant side effects. The side effects most often reported include myelosuppression, fever and chills, nausea, and vomiting.

fludarabine

A CYTOTOXIC anti-cancer drug. A brand name is Fludara.
References in periodicals archive ?
7 Combinations based on other purine analogues such as cladribine8 or pentostatin9 have shown similar activity, but it is uncertain whether they can replace fludarabine in FCR regimen.
A 47-year-old male underwent NMA allo-SCT (using fludarabine and total body irradiation (TBI) 1200 cGyl) from an HLA-identical sibling due to high-risk acute myeloblastic leukemia (AML).
Arzerra, indicated for the treatment of fludarabine and alemtuzumab refractory CLL, is currently available in the USA and Europe.
A repeat bone marrow biopsy performed two months later was consistent with lymphoma and 2 more cycles of fludarabine therapy were initiated.
The new agent was approved specifically for patients with CLL that has not responded to fludarabine (Fludara) and alemtuzumab (Campath).
The research team also involving researchers from University of Sienna, Italy have found PBOX- 15 was more effective than the current medication, fludarabine, used to treat the disease and also killed CLL cells that were resistant to treatment.
Tests in the laboratory show the drug is equally effective in treating the cells of patients who respond poorly to the current treatment, fludarabine.
Currently, the drug is approved to treat the disease in patients that have been treated with an alkylating agent and have failed fludarabine therapy.
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
The FDA has granted approval of its ANDA for fludarabine phosphate injection, 25 mg/ml.
Subsequently, the patient was started on fludarabine phosphate single-agent therapy and continued for 6 cycles to completion.